Tumor Necrosis Factor Inhibitors

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of whether the disease developed early or late in life, according to data published in Scientific Reports.

Greater adherence to TNF inhibitor therapy for rheumatoid arthritis led to fewer adverse events, with the optimal adherence threshold being approximately 60% of days covered, according to data published in Clinical Rheumatology.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.

Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

Baseline rituximab or JAK inhibitor use for rheumatoid arthritis was associated with worse COVID-19 severity, compared with TNF-inhibitor use, according to a speaker at the EULAR 2021 Congress.

Patients with rheumatoid arthritis in the United States made “substantial” medication changes in the first 3 months of the COVID-19 pandemic, with and without physician guidance, according to data published in Arthritis Care & Research.

The emergence of novel therapies over the last decade has turned the treatment of rheumatoid arthritis upside down.